ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs MXN
20.0779
0.00%
Brent Oil
72.72
0.00%
Bitcoin
97,283.09
-0.49%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Lantern Pharma Inc (LTRN) Cotización

Lantern Pharma Inc

Lantern Pharma Inc (LTRN)

NASDAQ
3.145
-0.032
(-1.01%)
Cerrado 20 Diciembre 3:00PM
Delayed by 15 minutes
3.25
0.105
(3.34%)
Fuera de horario: 5:51PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
3.25
Postura de Compra
3.00
Postura de Venta
3.25
Volume Operado de la Acción
39,336
3.10 Rango del Día 3.41
2.79 Rango de 52 semanas 11.99
Capitalización de Mercado [m]
35.05M
Precio Anterior
3.177
Precio de Apertura
3.17
Hora
100
@
3.25
(formt)
Última hora de negociación
Volumen financiero
US$ 125,619
Precio Promedio Ponderado
3.1935
Volumen promedio (3 m)
55,835
Acciones en circulación
10,784,725
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.11
Beneficio por acción (BPA)
-1.48
turnover
-
Beneficio neto
-15.96M

Acerca de Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-
Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was US$3.18. Over the last year, Lantern Pharma shares have traded in a share price range of US$ 2.79 to US$ 11.99.

Lantern Pharma currently has 10,784,725 shares in issue. The market capitalisation of Lantern Pharma is US$34.26 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -2.11.

LTRN Últimas noticias

Más noticias

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung...

09 Diciembre 2024
Business Wire

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC...

03 Diciembre 2024
Business Wire

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

The Phase 1b clinical trial design presented at SNO2024 combines LP-184 (STAR-001) with spironolactone to potentially enhance therapeutic response in recurrent glioblastoma (GBM) patients...

26 Noviembre 2024
Business Wire

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months U.S. clinical sites...

19 Noviembre 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Noviembre 2024
Edgar (US Regulatory)

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for...

07 Noviembre 2024
Business Wire

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the...

05 Noviembre 2024
Business Wire

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Webcast to be held Thursday, November 7th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”...

31 Octubre 2024
Business Wire

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...

23 Octubre 2024
Business Wire
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.37-10.22099447513.623.623.1684893.37669618CS
40.268.695652173912.994.882.8811003.54333098CS
12-0.59-15.36458333333.844.882.79558353.48495505CS
26-1.36-29.50108459874.615.12.79555143.81730202CS
52-0.89-21.49758454114.1411.992.791251406.29565414CS
156-4.22-56.49263721557.4711.992.38686165.92081915CS
260-11.91-78.56200527715.1624.842.38751679.50367141CS

LTRN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Lantern Pharma?
El precio actual de las acciones de Lantern Pharma es US$ 3.25
¿Cuántas acciones de Lantern Pharma están en circulación?
Lantern Pharma tiene 10,784,725 acciones en circulación
¿Cuál es la capitalización de mercado de Lantern Pharma?
La capitalización de mercado de Lantern Pharma es USD 34.26M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Lantern Pharma?
Lantern Pharma ha negociado en un rango de US$ 2.79 a US$ 11.99 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Lantern Pharma?
El ratio precio/beneficio de Lantern Pharma es -2.11
¿Cuál es la moneda de reporte de Lantern Pharma?
Lantern Pharma presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Lantern Pharma?
El último beneficio anual de Lantern Pharma es USD -15.96M
¿Cuál es la dirección registrada de Lantern Pharma?
La dirección registrada de Lantern Pharma es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿En qué sector industrial opera Lantern Pharma?
Lantern Pharma opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
120.01M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
76.64M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
33.95M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.61k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
120.4M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.18M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.18M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.23M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.14M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

LTRN Discussion

Ver más
Monksdream Monksdream 4 meses hace
LTRN under $5
👍️0
anabu9 anabu9 4 meses hace
Finally an UP day. 'hope institutions will see this nugget soon
👍️0
FALCON1 FALCON1 5 meses hace
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
dinogreeves dinogreeves 8 meses hace
Nice drop
🕳️ 1 🪦 1 ⚰️ 1
Monksdream Monksdream 8 meses hace
LTRN under $10
👍️0
Monksdream Monksdream 9 meses hace
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
dinogreeves dinogreeves 9 meses hace
Monk, take a look at ANV*S. Data is due sometime in April, Parkinsons and Alzheimers. They just did a private placement on Friday and another one today to an institutional investor. "Subject to Certain Conditions". Looks like April is go time.
👍️0
dinogreeves dinogreeves 9 meses hace
I think we can revisit the high again hopefully this week. Been here since 7.20
🖕🏻 1
spartex spartex 9 meses hace
10-K filing, Earnings Webcast, Presentation in link below from LTRN company website


https://ir.lanternpharma.com/news-events/press-releases/detail/150/lantern-pharma-reports-fourth-quarter-fiscal-year-2023
👍️0
Monksdream Monksdream 9 meses hace
LTRN new 52 hi
👍️0
dinogreeves dinogreeves 9 meses hace
Another very good day today.
👍️0
Monksdream Monksdream 9 meses hace
LTRN 10Q due 3/18
👍️0
dinogreeves dinogreeves 9 meses hace
Very good move on Friday.
🪦 1 ☠️ 1 ⚰️ 1 ⚱️ 1
dinogreeves dinogreeves 9 meses hace
This company will see 3 digit dollars, how soon? All depends on just one science behind their Artificial Intelligence to decode one cancer indication the rest will be history.
👍️0
dinogreeves dinogreeves 9 meses hace
This is going to have one heck of a run.
👍️0
Tremors! Tremors! 9 meses hace
Will they break 10.00!??
👍️0
Roily23 Roily23 10 meses hace
👍️0
Roily23 Roily23 10 meses hace
AI is the next .com and AI's application in medicine and pharma will be a game changer.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
👍️0

Su Consulta Reciente

NASDAQ
LTRN
Lantern Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados